Emistat FT
Generic Name
Ondansetron
Manufacturer
Square Pharmaceuticals Ltd.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| emistat ft 4 mg flash tablet | ৳ 6.00 | ৳ 60.00 |
| emistat ft 8 mg flash tablet | ৳ 11.00 | ৳ 110.00 |
Description
Overview of the medicine
Emistat FT contains Ondansetron, a potent and highly selective 5-HT3 receptor antagonist. It is used for the prevention and treatment of nausea and vomiting induced by chemotherapy, radiotherapy, and surgery.
Uses & Indications
Dosage
Adults
Chemotherapy-induced nausea/vomiting: 8 mg orally 30 minutes before chemotherapy, then 8 mg 8 and 16 hours after the first dose. Radiotherapy-induced nausea/vomiting: 8 mg orally 1-2 hours before radiotherapy, then 8 mg every 8 hours for up to 5 days. PONV: 8 mg orally 1 hour before anesthesia, or 4-8 mg orally as needed post-surgery.
Elderly
No dose adjustment required for patients aged 65-74 years. For patients aged 75 years or older, the initial IV dose should not exceed 16 mg.
Renal_impairment
No dose adjustment needed for renal impairment. Clearance and half-life are not significantly affected.
How to Take
Place the Emistat FT tablet on the tongue. It will rapidly disintegrate and can be swallowed with or without water. Do not chew.
Mechanism of Action
Ondansetron selectively blocks 5-HT3 receptors located both peripherally on vagal nerve terminals and centrally in the chemoreceptor trigger zone (CTZ). This action prevents serotonin from binding to these receptors, thereby inhibiting the vomiting reflex.
Pharmacokinetics
Onset
Oral: 30-60 minutes
Excretion
Mainly through urine (approx. 5% as unchanged drug), with a small amount in feces.
Half life
Approximately 3 hours in adults, up to 5 hours in elderly.
Absorption
Rapidly and completely absorbed from the gastrointestinal tract, though subject to first-pass metabolism. Bioavailability is approximately 60%.
Metabolism
Extensively metabolized in the liver by cytochrome P450 enzymes (CYP2D6, CYP1A2, CYP3A4).
Side Effects
Contraindications
- •Hypersensitivity to Ondansetron or any component of the formulation.
- •Concomitant use with apomorphine.
Drug Interactions
Tramadol
May reduce the analgesic effect of tramadol.
Apomorphine
Concomitant use is contraindicated due to profound hypotension and loss of consciousness.
QT-prolonging drugs
Caution advised, as Ondansetron can prolong the QT interval.
Storage
Store in a cool, dry place below 30°C, away from light and moisture. Keep out of reach of children.
Overdose
Symptoms of overdose include transient blindness, severe constipation, hypotension, and vasovagal episodes. Management is symptomatic and supportive.
Pregnancy & Lactation
Pregnancy Category B. Use only if clearly needed. Excretion into human milk is unknown, so caution advised during lactation.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
Typically 24-36 months from manufacturing date.
Availability
Available in all pharmacies in Bangladesh
Approval Status
Approved by DGDA
Patent Status
Generic available, original patent expired
WHO Essential Medicine
YesAlternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine
More Medicines
Explore other medicines you might be interested in